Dr Neela Patel, Chief Business Officer at Bonum Therapeutics, offers advice on how to negotiate a winning deal in biopharma that meets investors’, buyers’ and sellers’ goals. Business development (BD) is an essential ingredient to the success of early-stage companies, whether they plan to exit through M&A, IPO, or have… Read More
News that the UK is supporting two new initiatives to help further the development of antimicrobials alongside other solutions to tackle resistant infections is welcome news for a sector that has, in recent years, struggled to attract the funding and attention it deserves. The Pathways to Antimicrobial Clinical Efficacy… Read More
Stefanie Dedeurwaerdere is Global Strategy Lead for Pipeline Development in Global Epilepsy & Rare Syndromes at UCB. In her day-to-day role, she is responsible for the development of UCB’s epilepsy discovery strategy, working with researchers to advance understanding of epilepsies while ensuring candidates for a future clinical… Read More
Listen to this article on the DDW Podcast: James Peach is the Co-Founder and CEO of Human Centric Drug Discovery (HCDD), an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process. Peach shared his insight with DDW’s Megan Thomas. MT: In… Read More
DDW Editor Reece Armstrong asks whether artificial intelligence (AI) is the magic bullet many think it is. To reflect on another year in pharma is to think of the major stories and trends that have made impact within the industry. Often this can be drug approvals, exciting research… Read More
DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on the impact of artificial intelligence (AI), machine learning (ML) and automation in… Read More
Dr Pandora Pound, Fellow Oxford Centre for Animal Ethics explores the hinderances of animal testing in pharma and why new technologies such AI, genomics and synthetic biology can further… Read More
DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on what to expect from cancer research and immunotherapies. Greg Rossi, Senior Vice… Read More
Over the three days of Advanced Therapies Week (ATW) 2024 in Miami, Florida, US, 16-19 January 2024, DDW’s Megan Thomas heard from attendees about the obstacles the sector needs to overcome to succeed. Viral vector manufacturing At the Advanced Therapies Awards ceremony, Dr Luigi Naldini,… Read More
Fibrocor Therapeutics, a developer of novel therapeutics to treat fibrosis, recently appointed Piet Wigerinck as Chief Scientific Advisor. Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. DDW’s Megan Thomas caught up with Wigerinck to learn more about his work with small molecules for fibrosis research. … Read More
The annual Genesis conference took place at the end of 2023 in London, bringing together key opinion leaders, investors and innovators from across the life sciences sector to exchange insights, debate trends and generate deals. DDW’s Megan Thomas attended and reflects on highlights of the programme. Stacking… Read More
Cancer Research Horizon’s Innovation Summit 2023 took place on 21 November 2023 at the Royal Society of Medicine, and included talks from researchers translating their research, as well as networking with members of the entrepreneurial ecosystem. DDW’s Megan Thomas spoke to a range of attendees. Trends… Read More
Digital biomarkers promise to transform preventive medicine and clinical trials, but also raise issues of security, regulation and potential disparities in access. Deepika Khedekar, Clinical Trial Lead at IQVIA, provides an overview of the pros and cons, and suggests a possible solution. The human body, a… Read More
DDW’s Megan Thomas speaks to Jennifer Cann, Director of Pathology at Virscio, a company solving human health challenges through biomedical research. MT: Can you provide a top line summary of your research? JC: As Virscio’s Director of Pathology, I provide exploratory and translational pathology… Read More
Over the past several years, Dr Jo Varshney, Founder of VeriSIM Life, has front-led numerous collaborative engagements with a host of biopharma companies, government agencies, academic/medical institutes and industry innovators. Here, she discusses with DDW’s Megan Thomas the impact of AI and ML on the drug discovery process. MT:… Read More
Editor Reece Armstrong provides an introduction to the Fall 2023 issue of Drug Discovery World. Find out more about the issue and how to read it. That this issue should feature a market report on the state of the United Kingdom’s drug discovery… Read More
